科研速览 · Science Skim继续刷下去 · Keep skimming →
◆ Signal Transduction and Targeted Therapy2026-02-11· Chikungunya

Investigation of a clinical trial drug VV261 as a potent antiviral candidate against Chikungunya virus

Yumin Zhang, Sheng Tang, Lu Chen, Shufen Song, Junyuan Cao, Guanghui Tian, Gengfu Xiao, Jingshan Shen, Leike Zhang

原始摘要(英文原文)· Original abstract
Chikungunya virus (CHIKV) is a single-strand positive-sense RNA virus belonging to the family Togaviridae. Since 2004, CHIKV outbreaks have become more frequent and widespread, affecting millions of people and establishing Chikungunya disease as a significant global public health issue. 1 In Asia, the Asian lineage (CHIKV-Asian) and the East-Central-South-African lineage (CHIKV-ECSA) have become the most prevalent. In July 2025, a large-scale outbreak occurred in Guangdong Province, China, resulting in more than 9000 confirmed cases. 2 To date, no drug has been approved for clinical therapy, highlighting the urgent need to develop effective treatments against CHIKV.
读原文 · Read the paper ↗

AI 追问PRO

登录后使用 AI 追问

讨论区

登录后参与讨论

相关论文 · Related

Investigation of a clinical trial drug VV261 as a potent antiviral candidate against Chikungunya virus — 科研速览 Science Skim